Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Digital AI in Hematology - Integration of the Scopio Labs x100 Scanner with Newly Implemented AI Capabilities into Routine Clinical Workflow

Christian Salib, Swati Bhardwaj, Shafinaz Hussein, Siraj El Jamal, Bruce Petersen, Eileen Scigliano, Francine R. Dembitzer, Julie Teruya-Feldstein

Blood (2021) 138 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2021-148821

Published: 2021

Journal Articles

Team-Based Learning in Medical School Hematology Course Improves Immediate Understanding but Not Long-Term Retention

Arielle L Langer, MDMPH, Adam Binder, MD, Eileen Scigliano, MD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-133834

Published: 2020

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Maria J. Nieto, MD, Eileen Scigliano, MD, Celia L. Grosskreutz, MD, Steven Fruchtman, MD, John Mascarenhas, MD, Keren Osman, MD, Adriana Malone, MD, Samuel Cytryn, Vesna Najfeld, PhD, Ronald Hoffman, MD, Luis Isola, MD

Blood (2011) 118 (21): 4534.

https://doi.org/10.1182/blood.V118.21.4534.4534

Published: 2011

Journal Articles

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Eileen Scigliano, MD, Celia Grosskreutz, MD, Steven Fruchtman, MD, Janice Gabrilove, MD, John Mandeli, PhD, Luis Isola, MD

Blood (2005) 106 (11): 5315.

https://doi.org/10.1182/blood.V106.11.5315.5315

Published: 2005

Journal Articles

Acute Graft Versus Host Disease after Nonmyeloablative Allogeneic Stem Cell Transplantation with Low-Dose TBI, Fludarabine and Antithymocyte Globulin (ATG).

Celia L. Grosskreutz, MD, Ronald Egan, Eileen Scigliano, MD, Steven M. Fruchtman, MD, Luis M. Isola, MD

Blood (2004) 104 (11): 1254.

https://doi.org/10.1182/blood.V104.11.1254.1254

Published: 2004

Journal Articles

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Eileen Scigliano, M.D., Celia L. Grosskreutz, M.D., Steven M. Fruchtman, M.D., Janice L. Gabrilove, M.D., John P. Mandeli, Ph.D., Luis M. Isola, M.D.

Blood (2004) 104 (11): 5225.

https://doi.org/10.1182/blood.V104.11.5225.5225

Published: 2004

NARROW

Digital AI in Hematology - Integration of the Scopio Labs x100 Scanner with Newly Implemented AI Capabilities into Routine Clinical Workflow

Team-Based Learning in Medical School Hematology Course Improves Immediate Understanding but Not Long-Term Retention

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Acute Graft Versus Host Disease after Nonmyeloablative Allogeneic Stem Cell Transplantation with Low-Dose TBI, Fludarabine and Antithymocyte Globulin (ATG).

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Digital AI in Hematology - Integration of the Scopio Labs x100 Scanner with Newly Implemented AI Capabilities into Routine Clinical Workflow

Team-Based Learning in Medical School Hematology Course Improves Immediate Understanding but Not Long-Term Retention

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Acute Graft Versus Host Disease after Nonmyeloablative Allogeneic Stem Cell Transplantation with Low-Dose TBI, Fludarabine and Antithymocyte Globulin (ATG).

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only